Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


World's first delivery of intra-arterial Avastin directly into brain tumor

NewYork-Presbyterian/Weill Cornell study opens blood-brain barrier to deliver high-dose chemotherapy to malignant brain tumors; may avoid common side effects of systemic chemotherapy

Neurosurgeons from NewYork-Presbyterian Hospital/Weill Cornell Medical Center performed the world's first intra-arterial cerebral infusion of Avastin (bevacizumab) directly into a patient's malignant brain tumor.

This novel intra-arterial (IA) technique may expose the cancer to higher doses of the drug therapy, while possibly sparing the patient common side effects of receiving the drug intravenously (IV) or throughout their body.

The investigative procedure -- called super selective intra-arterial cerebral infusion of Avastin -- has been successfully performed on five patients with promising results. Details of the first case are scheduled for publication in the next issue of Journal of Experimental Therapeutics and Oncology.

The researchers are currently enrolling patients for the Phase I study, which will test the safety and tolerability of this new method of drug delivery. If proven successful, NewYork-Presbyterian/Weill Cornell physician-scientists believe that this promising method may one day offer patients a new and better therapy for glioblastoma multiforme (GBM), a common type of brain cancer that has not responded well to currently available therapies. In addition, the authors believe that this technique may herald the birth of a new field of "interventional neuro-oncology."

"We believe that infusing Avastin directly via the cerebral arteries deep into the site of the brain tumor may help to kill off the cancer cells hiding within the tumor and adjacent brain tissue," explains co-author and study co-principal investigator (PI) Dr. John A. Boockvar, associate professor of neurological surgery at Weill Cornell Medical College and director of the brain tumor research laboratory at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.

"We are combining the latest in drug treatment with a revolutionary delivery technique, which could potentially be more effective than currently available treatments," says co-author and co-PI, Dr. Howard Riina, co-director of interventional neuroradiology at NewYork-Presbyterian Hospital/Weill Cornell Medical Center and associate professor of neurological surgery, neurology and radiology at Weill Cornell Medical College.

Because of the blood-brain barrier (BBB), which prevents many IV-administered drugs from penetrating the blood vessel walls sufficiently in order to get into the brain, no one knows for sure if current drugs actually get into the brain after IV infusion.

"This new technique may be a way to get through that barrier and deliver higher doses of drug to the tumor with less toxicity to the patient," says Dr. Boockvar.

To deliver the drug, neurosurgeons direct a hair-thin microcatheter through blood vessels in the body, via the carotid artery running up the neck, and then into the smaller arteries deep in the brain. Upon arriving at the tumor site, a drug to open the blood-brain barrier is injected. After the BBB is temporarily opened -- a window of time lasting approximately five minutes -- the chemotherapeutic agent Avastin is injected directly into the malignant tumor.

Participants in the trial will be given varying doses of the drug in order to test which dose is best tolerated. Following this Phase I trial, the researchers plan to immediately begin a Phase II trial to test the technique's efficacy.

"This potential new drug delivery system demonstrates translational research from the Brain and Spine Center of NewYork-Presbyterian Hospital/Weill Cornell Medical Center at its best," says Dr. Philip E. Stieg, chairman of neurological surgery at Weill Cornell Medical College and neurosurgeon-in-chief at NewYork-Presbyterian/Weill Cornell. "If proven successful, it is a promising move forward for patients dealing with resistant brain tumors."

The current standard of care is to give patients with GBM the drug bevacizumab (Avastin) intravenously (IV) -- delivering the drug directly into a vein. The drug works by slowing the growth of new blood vessels within tumors, cutting off the life-giving blood and then causing the cancer cells to die. In May 2009, the FDA approved Avastin for the treatment of GBM.

Study researchers are currently recruiting males or females, 18 years of age or older, with documented diagnosis of relapsed GBM, anaplastic astrocytoma (AA) or anaplastic mixed oligoastrocytoma (AOA) -- two other types of brain tumors. The authors have no financial disclosures related to the study.

Study co-authors include Drs. Justin Fraser and Jared Knopman of Weill Cornell Medical College, and Dr. Ronald Scheff and Sherese Fralin, R.N., of NewYork-Presbyterian Hospital/Weill Cornell Medical Center.

For more information, patients may call (866) NYP-NEWS.

NewYork-Presbyterian Hospital/Weill Cornell Medical Center

NewYork-Presbyterian Hospital/Weill Cornell Medical Center, located in New York City, is one of the leading academic medical centers in the world, comprising the teaching hospital NewYork-Presbyterian and Weill Cornell Medical College, the medical school of Cornell University. NewYork-Presbyterian/Weill Cornell provides state-of-the-art inpatient, ambulatory and preventive care in all areas of medicine, and is committed to excellence in patient care, education, research and community service. Weill Cornell physician-scientists have been responsible for many medical advances -- including the development of the Pap test for cervical cancer; the synthesis of penicillin; the first successful embryo-biopsy pregnancy and birth in the U.S.; the first clinical trial for gene therapy for Parkinson's disease; the first indication of bone marrow's critical role in tumor growth; and, most recently, the world's first successful use of deep brain stimulation to treat a minimally conscious brain-injured patient. NewYork-Presbyterian Hospital also comprises NewYork-Presbyterian Hospital/Columbia University Medical Center, NewYork-Presbyterian Morgan Stanley Children's Hospital, NewYork-Presbyterian Hospital/Westchester Division and NewYork-Presbyterian Hospital/The Allen Hospital. NewYork-Presbyterian is the #1 hospital in the New York metropolitan area and is consistently ranked among the best academic medical institutions in the nation, according to U.S.News & World Report. Weill Cornell Medical College is the first U.S. medical college to offer a medical degree overseas and maintains a strong global presence in Austria, Brazil, Haiti, Tanzania, Turkey and Qatar.

John Rodgers | EurekAlert!
Further information:

More articles from Health and Medicine:

nachricht Advanced analysis of brain structure shape may track progression to Alzheimer's disease
26.10.2016 | Massachusetts General Hospital

nachricht Indian roadside refuse fires produce toxic rainbow
26.10.2016 | Duke University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Etching Microstructures with Lasers

Ultrafast lasers have introduced new possibilities in engraving ultrafine structures, and scientists are now also investigating how to use them to etch microstructures into thin glass. There are possible applications in analytics (lab on a chip) and especially in electronics and the consumer sector, where great interest has been shown.

This new method was born of a surprising phenomenon: irradiating glass in a particular way with an ultrafast laser has the effect of making the glass up to a...

Im Focus: Light-driven atomic rotations excite magnetic waves

Terahertz excitation of selected crystal vibrations leads to an effective magnetic field that drives coherent spin motion

Controlling functional properties by light is one of the grand goals in modern condensed matter physics and materials science. A new study now demonstrates how...

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

The gene of autumn colours

27.10.2016 | Life Sciences

Polymer scaffolds build a better pill to swallow

27.10.2016 | Life Sciences

Greater Range and Longer Lifetime

26.10.2016 | Power and Electrical Engineering

More VideoLinks >>>